Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article · Related *content* · Metrics ...

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  EurekAlert

Philadelphia, January 15, 2019 - A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology ...

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

Retinal Vein Occlusion Market Analysis & Trends to 2025| Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals  Weekly Wall

Los Angeles, United State, April 10, 2019– The research study presented in this report offers a complete and intelligent analysis of the competition, segmentation ...

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Laser-induced chorioretinal anastomosis can lessen CRVO treatment burden  Healio

Adding laser-induced chorioretinal anastomosis to anti-VEGF treatment for central retinal vein occlusion can reduce the number of injections needed, according ...

Retinal Vein Occlusion Therapeutics Market Research Study including Growth Factors, Types and Application by regions from 2019 to 2023  Current News Magazine

Compare the Retinal Vein Occlusion Therapeutics Market with expected revenue in next Five-Year. The Global Retinal Vein Occlusion Therapeutics Market are ...

Global Retinal Vein Occlusion Market Research Report - Forcast To 2023  Market News Biz

Introduction Retinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two ...

Allergan to resume marketing of macular edema treatment  Korea Biomedical Review

Allergan Korea said Tuesday that it has started re-marketing Ozurdex (ingredient: dexamethasone), a steroid eye implant for macular edema.

Study Shows Aflibercept Could Impact Endothelium Thickness  MD Magazine

Investigators found that intravitreal administration of aflibercept might alter the corneal endothelium within 6 months of their first injection.

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 12.4% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. with ticker code (REGN) now have 21 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Avastin as effective as Eylea for treating central retinal vein occlusion  National Institutes of Health

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Global Retinal Vein Occlusion Therapeutics Market Study 2019-2025: Sanofi Aventis, Valeant Pharmaceuticals, Allergan  Crypto News Today

This report analyzes the Global Retinal Vein Occlusion Therapeutics market size (production, value, capacity and consumption) in key regions like North ...

Global Retinal Vein Occlusion Therapeutics Market 2018: Countries, Industry Size, Challenges, Drivers and Technology Forecast to 2023  Washington DC Herald

Retinal Vein Occlusion Therapeutics Market Report will review upcoming market trends with technology advancement, development planning and production ...

Researchers confirm link between retinal vein occlusion, heart attack  Cardiovascular Business

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase ...

Ophthalmic Suspension Market Analysis Revealing Key Drivers, Growth Trends and Competitive Analysis through 2023 |  Medgadget

The suspension in the form of used to treat eye infections and related symptoms are generally termed as ophthalmic suspension. Generally it used in a.

Treatment arms for CRVO yield no difference in visual acuity results  Healio

BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in ...

Aflibercept Benefits Bevacizumab-Unresponsive Diabetic Retinopathy Patients  MD Magazine

A new analysis of an ongoing clinical study offers insights for treating retinal vein occlusion in poor responders to bevacizumab.

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial  The Lancet

Microsatellite-stable metastatic colorectal cancer is typically unresponsive to immunotherapy. This phase 3 study was designed to assess atezolizumab plus ...

US, UK trials underway to compare treatments for CRVO  Healio

KOLOA, Hawaii — Not long ago, there were no effective treatments for central retinal vein occlusion; now there are multiple treatments, Michael S. Ip, MD, said at ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Port Delivery System reduces neovascular AMD treatment burden  medwireNews

medwireNews: The Port Delivery System (PDS) with ranibizumab has the potential to reduce the burden of treatment for patients with neovascular.

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

What does Novartis' eye business envision without Alcon? Digital M&A, for one thing  FiercePharma

Now that Alcon is officially off on its own, what is Novartis and its remaining eye medicine business looking at next? Cutting-edge innovations, including gene ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

VIDEO: SCORE2 and LEAVO trials underway to compare CRVO treatments  Healio

KOLOA, Hawaii ― At Hawaiian Eye 2017, Michael S. Ip, MD, updates colleagues on the U.S.-based SCORE2 trial and the U.K.-based LEAVO trial, both of which ...

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

CIExpert on Canada Life's individual CI upgrade | COVER  COVER

'Solid improvements that will increase claims paid,' says Alan Lakey.

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment  Bel Marra Health

Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where the main vein of the retina has become blocked. Much like other organs of ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Cheap Avastin as effective as Eylea in CRVO  European Biotechnology

A study conducted by an NIH institute proves Roche's Avastin is as effective as Regeneron's Eylea, a drug that costs 30 times more than Roche's antibody.

Intravitreal corticosteroid implant vs intravitreal ranibizumab for th | DDDT  Dove Medical Press

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials Qingquan Wei,1 ...

Laser Speckle Flowgraphy Can Assist in CRVO Prognosis  Medscape

Laser speckle flowgraphy may offer a noninvasive method of assessing ocular blood flow in patients with central retinal vein occlusion (CRVO), according to a ...

Vascular Endothelial Growth Factor B Market | Global Research Insight 2018-2023  TheCells

Global Vascular Endothelial Growth Factor B Insight. Get industry insights and important projections for the market in upcoming quarters with the Global Vascular ...

SCORE2 subanalysis: Visual gains made after treatment switch  Healio

WAIKOLOA, Hawaii — Visual acuity letter score and central subfield thickness both improved in eyes treated with aflibercept after a poor response to ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Retinal Vein Occlusion Therapeutics Market to Reflect Steady Growth Rate by 2021 | Kentucky Breaking News Updates  Kentucky Journal 24

Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after ...

Case Report Highlights Acute Central Retinal Vein Occlusion in Scleroderma Patient  Scleroderma News

Researchers in Saudi Arabia at King Fahd Hospital of the University and the University of Dammam reported a case of a male patient with scleroderma who was ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Treatment switching outcomes in patients With macular edema | JAMA  MD Linx

Researchers performed this secondary analysis of a nonrandomized trial in which 49 patients with central retinal or hemiretinal vein occlusion responded poorly ...

Vascular Endothelial Growth Factor B | Global Market Detailed Study 2018-2023  SteerFeed

A research report on “Global Vascular Endothelial Growth Factor B Market 2018 Industry Research Report” is being published by Researchunt.com. This is a key ...

FDA OKs Aflibercept (Eylea) for All Retinal Vein Occlusions  Medscape

The US Food and Drug Administration (FDA) has expanded the indication of aflibercept (Eylea, Regeneron) injection to include all forms of macular edema after ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

BLOG: Laser still has an important role in diabetic eye disease  Healio

Ophthalmology Blogs | Mali | There is no question that the introduction of anti-VEGF agents has dramatically changed the landscape of how surgeons approach ...

Branch Retinal Artery Occlusion (BRAO): Causes, Symptoms, Diagnosis, and Treatment  Bel Marra Health

Branch retinal artery occlusion or BRAO is a vision-related disease-causing long-term vision problems. It is caused due to reduced or blocked blood flow.

New gene therapy for vision loss proven safe in humans  Medical Xpress

In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to ...

Catheter complications . . . and other stories  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l1045 (Published 14 March 2019) Cite this as: BMJ 2019;364:l1045. Article · Related *content* · Metrics ...

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment  Bel Marra Health

Eye strokes can come one suddenly and result in partial or complete loss of vision. Learn about cause, risk factors and treatment options.

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion  GlobeNewswire

ALPHARETTA, Ga., March 06, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing ...

Switching to Aflibercept Demonstrates Improvement in VA, CST for Poor Responders to Bevacizumab in SCORE2  MD Magazine

Those who were switched to aflibercept improved 9 letters of VA, and 110 µm in CST from months 6 to 12.

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  Business Wire

Genentech's investigational Port Delivery System with ranibizumab (PDS) is a small, refillable device, slightly longer than a grain of rice, surgically implanted in ...

RETINA-AI Releases Android Version of Fluid-Intelligence -- World's First Mobile Artificial Intelligence App for Eye Care Providers  AiThority

RETINA-AI has released an Android version of its app Fluid-Intelligence, the world's first mobile artificial intelligence (AI) app for eye care providers. The app can ...

Ophthalmic Suspension Market 2019 Competitor Analysis By Novartis, ALLERGAN, Pfizer, Merck, Valeant Pharmaceuticals, Bayer, Genentech, Falcon Group, Ciron Drugs And Pharmaceuticals Private Limited  industryreports24.com

Global Ophthalmic Suspension Market research report is one of the key factors used to maintain competitiveness over competitors. Ophthalmic Suspension ...

Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases  Healio

VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and ...

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Associated Press

Press release *content* from BusinessWire. The AP news staff was not involved in its creation.

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the Speculative Spotlight  FDA Headlines

Dec 7, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the. Regeneron Pharmaceuticals Inc ...

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-m | OPTH  Dove Medical Press

Tetsuya Muto, Shigeki Machida Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan Purpose: To determine ...

Revealing the retina: Graphene corneal contact lens provides robust, irritation-free topographic electroretinography  Phys.org

Our vision can be damaged or lost by damage to the retina—a sensory membrane lining the back of the eye that senses light, converting the image formed into ...

Fast Action Can Save Sight if Retina Is Detached or Blocked  New York Times

Modern treatments can do wonders if they are begun before the damage to the eye is irreversible.

Clearside Scraps Xipere for RVO after Phase III Failure; Shares Tumble 58%  Genetic Engineering & Biotechnology News

Clearside Biomedical lost more than half its stock value today after it said it was scrapping clinical development of its lead candidate Xipere (formerly ...

High Blood Pressure, High Cholesterol May Be Associated With Retinal Vascular Disease  Science Daily (press release)

High blood pressure and high cholesterol levels appear to be risk factors for retinal vein occlusion, a condition that causes vision loss, according to a new article.

Increase in choroidal thickness seen after CPAP therapy  Healio

Patients with obstructive sleep apnea syndrome who underwent continuous positive airway pressure therapy experienced an increase in choroidal thickness ...

Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron  Seeking Alpha

Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.

Bevacizumab, Ranibizumab Biosimilars Proven Effective, Safe for Retina Diseases  MD Magazine

The cheaper intravitreal anti-VEGF options improved visual acuity in the eyes of patients with 5 different retinal conditions.

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

The eye jab that can banish blind spots  Daily Mail

Clive Woodington had Central Retinal Vein Occlusion (CRVO), a distressing condition that can lead to blindness in the affected eye.

Novartis nAMD Treatment Brolucizumab Shows Superiority Against Regeneron's Eylea at Two Years  BioSpace

With *fresh* two-year data in hand, Novartis remains focused on seeking regulatory approval for brolucizumab, an ophthalmology drug for the treatment of ...

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

CRAO and Stroke Risk: Is Neurological Evaluation Warranted?  Medscape

Patients with central retinal artery occlusion may be at an increased risk for stroke and may benefit from prompt neurological evaluation, according to a new ...

Bayer receives new approval for Eylea eye treatment in Japan  Reuters

Bayer HealthCare has received approval from Japan's Ministry of Health to treat macular edema secondary to central retinal vein occlusion (CRVO) with its ...

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

Clearside Biomedical: Buy Or Sell Before 2018 Catalysts  Seeking Alpha

The 8-week data from the first phase 3 trial (SAPPHIRE) in treating macular edema due to retinal vein occlusion is expected in Q4 (a big binary event for the st.

Topical timolol-dorzolamide combined with anti-VEGF could better treat macular edema  Healio

PHILADELPHIA – An ongoing study suggests that topical timolol-dorzolamide can reduce central subfield thickness in patients with persistent macular edema ...

Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN suffered a setback when the FDA issued a complete response letter (CRL) to its supplemental Biologics License.

Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies  Nasdaq

Aerie Pharmaceuticals, Inc. AERI announced that the FDA has reviewed the Investigational New Drug (IND) application for AR-1105 (dexamethasone ...

Therapy applied directly inside the eye best for treating uveitic macular edema  Medical Xpress

Delivery of corticosteroids directly into the eye is more effective than injections adjacent to the eye, according to results from a comparative clinical trial of ...

Retinal Vein Occlusion Therapeutics Market: Global Distributors, Traders and Dealers Marketing Channel Future Trend Prediction to 2025  Washington DC Herald

Global Retinal Vein Occlusion Therapeutics Market Insights, forecast to 2025 mainly highlights thoughtful facts and knowledge of Retinal Vein Occlusion ...

Two-year data confirm efficacy of EYLEA® (aflibercept solution for injection) Treat and Extend dosi  PharmiWeb.com

Significant visual acuity gains observed in the first year of treatment with aflibercept were largely maintained for 96 weeks· Up to 60% of patients had an injection ...

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

First human test of robotic eye surgery a success  Medical Xpress

Researchers from the University of Oxford have completed the first successful trial of robot-assisted retinal surgery.

VEGF Inhibition Improves Visual Acuity in Macular Edema  Medscape

Ranibizumab improved visual acuity at 6 months in patients with macular edema secondary to ischemic branch retinal vein occlusion, whether or not they ...

RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye-Care Providers: Fluid Intelligence by RETINA-AI  PR Newswire

HOUSTON, July 17, 2018 /PRNewswire/ -- RETINA-AI has developed and released the first Artificial Intelligence mobile app for eye-care providers. This app ...

Faulty molecular master switch may contribute to AMD: TGF-beta signaling governs immune cell function in the eye  Science Daily

A signaling pathway controlled by transforming growth factor beta (TGF-beta) could be involved in the progression of age-related macular degeneration (AMD).

Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate  PRNewswire

PALO ALTO, Calif., Dec. 21, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel...

» Load more